EBV-Specific TCR for Cost-Effective Adoptive Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for EBV-associated tumors are inadequate, with conventional therapies showing variable responses and high costs associated with adoptive immunotherapy using antigen-specific T cells, limiting their clinical application and commercialization.
Innovation Solution
Development of a T-cell receptor (TCR) highly specific for epitopes derived from the latent membrane protein 1 (LMP1) of Epstein-Barr Virus (EBV), enabling the production of EBV-specific T cells for use in adoptive immunotherapy, including nucleotide sequences, vectors, and host cells for treating EBV-associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adoptive immunotherapy using antigen-specific T cells is used to treat EBV-associated tumors, then treatment effectiveness is improved, but cost increases significantly
Solution Approach 1:
The patent creates a copy of the therapeutic T cells by generating a TCR gene product that can be introduced into any T cell to produce antigen-specific T cells. Instead of relying on expensive patient-specific T cell culture, the TCR gene sequence serves as a template to produce identical functional copies of the therapeutic T cells through viral vector delivery, dramatically reducing cost while maintaining treatment effectiveness.
Solution Approach 2:
The patent performs preliminary action by identifying and characterizing the TCR gene sequence before treatment. The TCR gene has been pre-selected and validated for its ability to recognize EBV antigens, so the actual treatment only requires delivering this pre-prepared gene to T cells, eliminating the need for time-consuming and expensive in vitro T cell activation and expansion processes.
2Quantity of substance
If conventional therapies are used for EBV-associated tumors, then treatment cost is reduced, but treatment effectiveness decreases
Solution Approach 1:
The patent changes the fundamental parameter of treatment from conventional chemotherapy or antibody therapy to gene-based immunotherapy. By introducing the TCR gene into T cells, the treatment mechanism shifts to enable endogenous T cells to specifically recognize and kill EBV-positive tumor cells, achieving high effectiveness at lower cost compared to conventional therapies.
3Reliability
If patient-specific T cell culture is performed to achieve high avidity T cells, then treatment effectiveness is improved, but treatment time and complexity increase
Solution Approach 1:
The patent extracts the essential functional element (TCR gene sequence) from the complex process of patient-specific T cell culture. By isolating and using only the TCR gene, the treatment eliminates the time-consuming steps of T cell isolation, activation, expansion, and quality control, while still achieving high avidity antigen-specific T cells through simple viral vector delivery.
Data Source
AI summary
The present invention relates to an EBV antigen specific T-cell receptor and the use thereof. Specifically, the present invention provides T cells specific for LMP1 of EBV using a T-cell receptor which is highly specific for specific epitopes derived from an EBV antigen, LMP1. In addition, the EBV antigen specific T-cell can be used in the prevention or treatment of EBV-associated diseases.